Development of treatments for chronic rhinosinusitis and roots of allergic respiratory diseases
Sep 01, 2024
A root-allergic respiratory disease treatment that can replace existing injections has been developed.
A joint research team led by Professor Kim Joo-young of Yonsei University's Pharmacology Class, Professor Cho Hyung-joo of Severance Hospital, and Professor Park Joon-sang of Hongik University's Computer Engineering Department said they have developed a root-type treatment that can reduce side effects of injections, the existing treatment method for refractory nasopharyngitis, and increase patient convenience and treatment effectiveness.
The findings were published in the latest issue of the international journal Materials Today Bio (IF 8.7).
Chronic rhinosinusitis, which affects 30% of the world's population, causes nasal congestion and sneezing, which deteriorates the quality of daily life. Traditionally, it was treated with oral drugs or injections.
However, oral drugs (steroids) can cause side effects throughout the body beyond the treatment area when taken for a long time, and periodic injections (antibody treatments) may cause patient discomfort and eosinophilia side effects that increase eosinophils, a type of white blood cell.
To solve this problem, the research team paid attention to a protein treatment 'nanobody' with a size of 2 to 4 nm (nanometers, 1 billionth of a meter). At this time, the research team developed the nanobody to target IL-4Rα (interleukin-4 receptor alpha). IL-4Rα is a protein involved in immune response and inflammatory regulation.
The nanobody treatment developed by the research team increases the effectiveness of the treatment by directly touching the surface of the nasal cavity, which is an inflammatory area, unlike conventional treatments that eat or inject. In addition, it is composed of micro-particles of 1/1 billionth of a meter, and has high penetration into the inflammatory area. These non-invasive features can minimize patient discomfort.
Professor Cho Hyung-joo said, `The existing method of treatment by taking medicine or injection has been difficult in terms of various side effects, high cost, and patient inconvenience"We expect this study to help treat allergic respiratory diseases such as chronic rhinosinusitis through the creation of a treatment that sprays directly into the nasal cavity, which is an inflammatory site."
On the other hand, this study was conducted with the support of the convergence basic laboratory project (Professor Kim Joo-young, Research Foundation of Korea) in cooperation with the nanobody discovery team, in silico protein binding enhancement team, and clinical research team.
A joint research team led by Professor Kim Joo-young of Yonsei University's Pharmacology Class, Professor Cho Hyung-joo of Severance Hospital, and Professor Park Joon-sang of Hongik University's Computer Engineering Department said they have developed a root-type treatment that can reduce side effects of injections, the existing treatment method for refractory nasopharyngitis, and increase patient convenience and treatment effectiveness.
The findings were published in the latest issue of the international journal Materials Today Bio (IF 8.7).
Chronic rhinosinusitis, which affects 30% of the world's population, causes nasal congestion and sneezing, which deteriorates the quality of daily life. Traditionally, it was treated with oral drugs or injections.
However, oral drugs (steroids) can cause side effects throughout the body beyond the treatment area when taken for a long time, and periodic injections (antibody treatments) may cause patient discomfort and eosinophilia side effects that increase eosinophils, a type of white blood cell.
To solve this problem, the research team paid attention to a protein treatment 'nanobody' with a size of 2 to 4 nm (nanometers, 1 billionth of a meter). At this time, the research team developed the nanobody to target IL-4Rα (interleukin-4 receptor alpha). IL-4Rα is a protein involved in immune response and inflammatory regulation.
The nanobody treatment developed by the research team increases the effectiveness of the treatment by directly touching the surface of the nasal cavity, which is an inflammatory area, unlike conventional treatments that eat or inject. In addition, it is composed of micro-particles of 1/1 billionth of a meter, and has high penetration into the inflammatory area. These non-invasive features can minimize patient discomfort.
Professor Cho Hyung-joo said, `The existing method of treatment by taking medicine or injection has been difficult in terms of various side effects, high cost, and patient inconvenience"We expect this study to help treat allergic respiratory diseases such as chronic rhinosinusitis through the creation of a treatment that sprays directly into the nasal cavity, which is an inflammatory site."
On the other hand, this study was conducted with the support of the convergence basic laboratory project (Professor Kim Joo-young, Research Foundation of Korea) in cooperation with the nanobody discovery team, in silico protein binding enhancement team, and clinical research team.
|
bellho@sportschosun.com
